| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/27/2011 | WO2011011722A1 Substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mglur4 potentiators |
| 01/27/2011 | WO2011011721A2 Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
| 01/27/2011 | WO2011011710A1 Methods of treating viral infections |
| 01/27/2011 | WO2011011706A2 Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents |
| 01/27/2011 | WO2011011700A2 Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
| 01/27/2011 | WO2011011692A2 Methods of treating and preventing/reducing the likelihood of mesial temporal lobe epilepsy (tle) |
| 01/27/2011 | WO2011011665A1 Hemi-phorboxazole a derivatives and methods of their use |
| 01/27/2011 | WO2011011652A1 Therapeutic compounds |
| 01/27/2011 | WO2011011632A1 Methods and compositions for modulating membrane potential to influence cell behavior |
| 01/27/2011 | WO2011011607A1 Composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome |
| 01/27/2011 | WO2011011594A2 Intracellular toll-like receptors pathways and axonal degeneration |
| 01/27/2011 | WO2011011550A1 Treatment of liver disorders with pi3k inhibitors |
| 01/27/2011 | WO2011011541A1 Ferric citrate dosage forms |
| 01/27/2011 | WO2011011522A2 Potent small molecule inhibitors of autophagy, and methods of use thereof |
| 01/27/2011 | WO2011011514A1 Heteroaryl benzamides, compositions and methods of use |
| 01/27/2011 | WO2011011513A1 Inhibition of pathological bone formation |
| 01/27/2011 | WO2011011508A1 Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| 01/27/2011 | WO2011011506A1 Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| 01/27/2011 | WO2011011494A1 Imidazoazepinone compounds |
| 01/27/2011 | WO2011011486A1 Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection |
| 01/27/2011 | WO2011011474A1 Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| 01/27/2011 | WO2011011420A2 3, 4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor |
| 01/27/2011 | WO2011011418A1 Crude caffeine complex, improved food products using the crude caffeine complex, and methods of use thereof |
| 01/27/2011 | WO2011011376A2 Methods for the preparation and use of aqueous solutions of magnesium valproate hydrate and l-carnitine |
| 01/27/2011 | WO2011011351A2 A stable pharmaceutical omeprazole formulation for oral administration |
| 01/27/2011 | WO2011011330A2 Inhibitors of d-amino acid oxidase |
| 01/27/2011 | WO2011011317A1 Vitamin c and vitamin k, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant |
| 01/27/2011 | WO2011011312A1 Quinolinone pde2 inhibitors |
| 01/27/2011 | WO2011011303A1 Inhibitors of flaviviridae viruses |
| 01/27/2011 | WO2011011277A1 Inhibitor(s) of transporters or uptake of monoaminergic neurotransmitters |
| 01/27/2011 | WO2011011252A1 Methods of attenuating the loss of functional status |
| 01/27/2011 | WO2011011238A1 Inhibiting antipsychotic-induced weight gain |
| 01/27/2011 | WO2011011235A1 Treatment of disorders associated with g protein-coupled receptor 35 (gpr35) |
| 01/27/2011 | WO2011011232A1 Dual-acting oxazole antihypertensive agents |
| 01/27/2011 | WO2011011231A1 3-phenoxymethylpyrrolidine compounds |
| 01/27/2011 | WO2011011199A1 Combination therapies with ck2 modulators |
| 01/27/2011 | WO2011011186A2 Hdac inhibitors and therapeutic methods using the same |
| 01/27/2011 | WO2011011123A1 Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
| 01/27/2011 | WO2011011099A1 Multi-layered gradient vaginal ring |
| 01/27/2011 | WO2011011092A1 Methods and compositions to reduce oxidative stress |
| 01/27/2011 | WO2011011077A2 Microbially stable dispersion medium for emulsions |
| 01/27/2011 | WO2011011027A1 Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| 01/27/2011 | WO2011010715A1 Pr-set7 inhibitor |
| 01/27/2011 | WO2011010714A1 Anionic polymer, polyion complex using anionic polymer, ternary polymer composite, and pharmaceutical composition |
| 01/27/2011 | WO2011010706A1 Fgf21 cis-element binding substance |
| 01/27/2011 | WO2011010691A1 Polyion complex comprising phd2 expression inhibiting substance |
| 01/27/2011 | WO2011010682A1 Sterol derivative |
| 01/27/2011 | WO2011010645A1 Fentanyl-containing adhesive preparation for external use |
| 01/27/2011 | WO2011010583A1 Method for screening for oligonucleotide, and oligonucleotide library |
| 01/27/2011 | WO2011010556A1 Transdermal preparation |
| 01/27/2011 | WO2011010456A1 EXTERNAL PREPARATION CONTAINING NSAIDs AND METHOD FOR PRODUCING THE EXTERNAL PREPARATION |
| 01/27/2011 | WO2011010364A1 Compound having neurite-outgrowing activity |
| 01/27/2011 | WO2011010332A1 Process for preparing rel-(3r*,3as*,7as*)-3-benzyl-2-methyl-2,3, 3a,4,5,6,7,7a- octahydrobenzo[d]isoxazoi-4-one or a salt thereof |
| 01/27/2011 | WO2011010324A1 Oral pharmaceutical composition of rasagiline and process for preparing thereof |
| 01/27/2011 | WO2011010316A1 Pharmaceutical compositions of irbesartan |
| 01/27/2011 | WO2011010306A1 A3 adenosine receptor ligands for modulation of pigmentation |
| 01/27/2011 | WO2011010190A1 Antibacterial composition comprising fluoroquinlone such as norfloxacin together with tripmethoprim |
| 01/27/2011 | WO2011010174A1 Crystalline form i rosuvastatin zinc salt |
| 01/27/2011 | WO2011010132A1 Sustained-release composition comprising compound 600 |
| 01/27/2011 | WO2011010131A1 Compositions comprising an oxoisoquinoline methylbenzamide and a polymer |
| 01/27/2011 | WO2011010083A1 Indolyl-pyridone derivatives |
| 01/27/2011 | WO2011010075A1 Use of jasmonic acid derivative as a soothing agent |
| 01/27/2011 | WO2011010015A1 Piperidine compounds, method for preparing same, and pharmaceutical compositions containing same |
| 01/27/2011 | WO2011010014A1 Chromene derivatives, method for preparing same, and pharmaceutical compositions containing same |
| 01/27/2011 | WO2011010013A1 Acyl guanidine derivatives modulating the hedgehog protein signaling pathway |
| 01/27/2011 | WO2011009961A1 Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis |
| 01/27/2011 | WO2011009956A1 Injectable aqueous solution containing artesunate |
| 01/27/2011 | WO2011009951A1 1h-quinazoline-2, 4 -diones for use in the treatment of neuronal ceroid lipofuscinosis |
| 01/27/2011 | WO2011009943A1 Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders |
| 01/27/2011 | WO2011009898A1 Fused aminodihydro-oxazine derivatives |
| 01/27/2011 | WO2011009897A1 Fused aminodihydropyrimidone derivatives |
| 01/27/2011 | WO2011009890A2 Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives |
| 01/27/2011 | WO2011009883A1 Selective cb2 receptor agonists for use in the prevention or treatment of alcoholic liver disease |
| 01/27/2011 | WO2011009851A2 Walnut extracts for nutraceutical applications |
| 01/27/2011 | WO2011009845A1 Pyridone glucokinase activators |
| 01/27/2011 | WO2011009831A1 Process for the purification of olanzapine |
| 01/27/2011 | WO2011009827A1 Method of making cefquinome particles |
| 01/27/2011 | WO2011009826A2 Novel chalcone derivatives with cytotoxic activity |
| 01/27/2011 | WO2011009818A1 Beta 2 adrenergic receptor agonists such as terbutaline for use in the treatment of nocturnal hypoglycemia |
| 01/27/2011 | WO2011009714A2 Benzoquinolizinium salt derivatives as anticancer agents |
| 01/27/2011 | WO2011009697A1 Antisense oligomers targeting pcsk9 |
| 01/27/2011 | WO2011009695A1 New anti-angiogenic compounds |
| 01/27/2011 | WO2011009604A1 Oxidation-stabilized tamper-resistant dosage form |
| 01/27/2011 | WO2011009603A1 Tamper-resistant dosage form for oxidation-sensitive oploids |
| 01/27/2011 | WO2011009602A1 Hot-melt extruded controlled release dosage form |
| 01/27/2011 | WO2011009601A1 Cell protection in dialysis patients by administration of a creatine compound |
| 01/27/2011 | WO2011009484A1 Arylpyrazoles and arylisoxazoles and their use as pkd modulators |
| 01/27/2011 | WO2011009360A1 Pharmaceutical composition for treatment of type 2 diabetes in mammals including human beings |
| 01/27/2011 | WO2011009193A1 Combinations of curcummoids and mtor inhibitors for the treatment of tauopathies |
| 01/27/2011 | WO2010143803A3 New nicotinamide derivatives with anti-androgen effects, processes of preparing, and antiandrogens comprising the same |
| 01/27/2011 | WO2010142956A3 Aroylthiourea and arylthiocarbonylurea derivatives |
| 01/27/2011 | WO2010141726A3 Peptide dicer substrate agents and methods for their specific inhibition of gene expression |
| 01/27/2011 | WO2010141690A3 Indane analogs and use as pharmaceutical agents and process of making |
| 01/27/2011 | WO2010140139A3 Crystalline forms of 6-(1h- imadazol- 1-yl) -2-phenylquinazoline |
| 01/27/2011 | WO2010138820A3 N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation |
| 01/27/2011 | WO2010138652A4 Methods for treating kaposi sarcoma |
| 01/27/2011 | WO2010138210A8 Methods of saponifying xanthophyll esters and isolating xanthophylls |
| 01/27/2011 | WO2010135534A3 Compositions for the treatment of metastatic cancer and methods of use thereof |
| 01/27/2011 | WO2010134039A3 Mitochondrial activity inhibitors of cancer-initiating cells and use thereof |
| 01/27/2011 | WO2010133976A3 Substantially pure imatinib or a pharmaceutically acceptable salt thereof |